Canopy Growth Distributes 2026 Annual Meeting Materials and Urges Shareholders to Vote Ahead of September 25 Meeting Canopy Growth Corporation, a global company focused on the cannabis sector, has announced that it has mailed, or mailed notices regarding the availability…
AIVITA Biomedical Named 2026 Prix Galien USA “Best Startup” Nominee for Personalized Immunotherapy Innovation AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines and immunotherapies for infectious diseases and cancer, has been named a 2026 Prix Galien USA nominee in…
Amprion and MLM Medical Labs Expand Access to α-Synuclein Testing for Neurodegenerative Disease Trials Across Europe Amprion, a global leader in advancing the diagnosis and characterization of neurodegenerative disorders through seed amplification testing, has announced a strategic licensing collaboration with…
AbCellera Reports Positive Phase 2 Results for ABCL635, Advancing Long-Acting Non-Hormonal Treatment for Menopausal Hot Flashes AbCellera has announced encouraging top-line results from the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating ABCL635, an investigational antibody designed…
Multicenter Study Demonstrates Superior Outcomes with equicenta® CTM for Returning Performance Horses to Work Equine Performance Labs (EPL), the company behind equicenta® CTM, has announced the publication of new peer-reviewed clinical research demonstrating the potential of its regenerative therapy to…
Helen Branswell Named Recipient of the 2026 Kovler Prize for Trust in Life Science Journalism The Foundation for the National Institutes of Health (FNIH) has announced that renowned infectious disease journalist Helen Branswell, an award-winning correspondent with STAT, has been…
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Neuroplastogenic Candidate EB-003 Enveric Biosciences, a clinical-stage biotechnology company focused on developing next-generation neuroplastogenic small-molecule therapies for psychiatric and neurological disorders, has announced new preclinical findings that further…
Twist Bioscience Launches $250 Million Public Stock Offering to Support R&D, Manufacturing Expansion, and Long-Term Growth Twist Bioscience Corporation (Nasdaq: TWST), a biotechnology company recognized for its synthetic DNA technology platform and expanding portfolio of genomics and life sciences products,…
FUJIFILM Biotechnologies Appoints Maja Pedersen as President to Lead Next Phase of Global Growth and Operational Excellence FUJIFILM Biotechnologies has announced a significant leadership transition designed to support the company’s continued expansion and long-term strategic growth. The global contract development…
Zai Lab’s DLL3-Targeting ADC Receives FDA Orphan Drug Designation for Neuroendocrine Carcinomas Zai Lab Limited has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci,…
EU Approval Positions Datroway® as the Only TROP2-Targeted Therapy with Overall Survival Benefit in First-Line Metastatic TNBC The European Commission (EC) has approved Datroway® (datopotamab deruxtecan) as a monotherapy for the first-line treatment of adults with unresectable or metastatic triple-negative…
Contineum Therapeutics Reports Second Quarter 2026 Financial Results and Reaffirms Clinical Development Milestones Across Inflammatory and Fibrotic Disease Pipeline Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing differentiated small-molecule therapies for inflammatory and fibrotic diseases with significant unmet…